Unknown PHASE1 INTERVENTIONAL 5-arm NCT04178044

Phase Ⅰ Clinical Study Protocol of GB223 Monoclonal Antibody Injection

A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalated Phase Ⅰ Study to Evaluate the Safety, Tolerability, Pharmacokinetic(PK) and Pharmacodynamic(PD) of GB223 in Healthy Adult Subjects.

Sponsor: Genor Biopharma Co., Ltd.

Conditions Bone Tumor

Interventions GB223,119mg/kg GB223,140mg/kg GB223,21mg/kg GB223,63mg/kg GB223,7mg/kg

Updated 5 times since 2019 Last updated: Nov 24, 2019 Started: Nov 16, 2018 Primary completion: Dec 31, 2020 Completion: Apr 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Bone Tumor, this trial is ongoing. The trial is conducted by Genor Biopharma Co., Ltd. and has accumulated 5 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2022 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jan 2021 — Jan 2022 [monthly]

Recruiting PHASE1
Dec 2019 — Jan 2021 [monthly]

Recruiting PHASE1

First recorded

Nov 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genor Biopharma Co., Ltd.

Data source: Genor Biopharma Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China